Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Obesity Surgery
Published in: Obesity Surgery 1/2015

01-01-2015 | Brief Communication

How Physician Obesity Medicine Specialists Treated Obesity before 2012 New Drug Approvals

Authors: Stacy L. Schmidt, David Bryman, Frank L. Greenway, Ed J. Hendricks

Published in: Obesity Surgery | Issue 1/2015

Login to get access

Abstract

Background

A survey of obesity medicine specialists was conducted before the approval of new obesity medications in 2012.

Methods

An Internet survey was sent to obesity medicine specialists inquiring about their practice and prescribing habits.

Results

Twenty-five percent of 1992 obesity medicine specialists responded. They used stimulant obesity medication for longer and at higher doses than recommended in the package insert. Medications for other indications were used off-label alone and in combination for obesity treatment. Only 15 % saw surgical patients.

Conclusions

The survey is a baseline for when more obesity medications exist in 5 years. We hope discovering a lack of collaboration between obesity medical specialists and obesity surgeons will stimulate more team work that will benefit obese patients contemplating or undergoing obesity surgery.
Literature
1.
Sugarman P, Mitchell A, Frogley C, et al. Off-license prescribing and regulation in psychiatry: Current challenges require a new model of governance. Ther Adv Psychopharmacol. 2013;3(4):233–43.PubMedCentralPubMedCrossRef
2.
3.
Hendricks EJ, Rothman RB, Greenway FL. How physician obesity specialists use drugs to treat obesity. Obesity (Silver Spring). 2009;17(9):1730–5.CrossRef
4.
NHLBI. National heart, blood, and lung institute. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults—the evidence report. National institutes of health. Obes Res. 1998;6 Suppl 2:51S–209S.
5.
6.
Rosenstock J, Balas B, Charbonnel B, et al. T-emerge 2 study group. The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial. Diabetes Care. 2013;36(3):498–504.PubMedCentralPubMedCrossRef
7.
Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obesity (Lond). 2012;36(6):843–54.
8.
Greenway FL, Whitehouse MJ, Guttadauria M, et al. Rational design of a cobmination medication for the treatment of obesity. Obesity (Silver Spring). 2009;17(1):30–9.
9.
Stevens JR, Wilens TE, Stern TA. Using stimulants for attention-deficit/hyperactivity disorder: clinical approaches and challenges. Prim Care Companion CNS Disord 2013; 15(2).
10.
Anonymous. Health implications of obesity. National institutes of health consensus development conference statement. Ann Intern Med. 1985;103(6 part 2):1073–7.
11.
Frank A. The long-term management of obesity with continuing pharmacotherapy. Obes Res. 2004;12(11):1821–7.PubMedCrossRef
12.
Hendricks EJ, Greenway FL, Westman EC, et al. Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity. Obesity (Silver Spring). 2011;19(12):2351–60.CrossRef
13.
Hendricks EJ, Greenway FL. A study of abrupt phentermine cessation in patients in a weight management program. Am J Ther. 2011;18(4):292–9.PubMedCrossRef
14.
Hendricks EJ, Srisurapanont M, Schmidt SL, et al. Addiction potential of phentermine prescribed during long-term treatment. Int J Obesity (Lond). 2014;38(2):292–8.CrossRef
15.
Sharma AM, Kushner RF. A proposed clinical staging system for obesity. Int J Obesity (Lond). 2009;33(3):289–95.CrossRef
16.
Padwal RS, Pajewski NM, Allison DB, et al. Using the Edmonton obesity staging system to predict mortality in a population-representative cohort of people with overweight and obesity. CMAJ. 2011;183(14):E1059–66.PubMedCentralPubMedCrossRef
17.
Rothman RB. Treatment of obesity with “Combination” pharmacotherapy. Am J Ther. 2010;17(6):596–603.PubMedCrossRef
18.
Heber D, Greenway FL, Kaplan LM, et al. Endocrine and nutritional management of the post-bariatric surgery patient: and endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(11):4823–43.PubMedCrossRef
19.
Dixon JB, Schacter LM, O’Brien PE, et al. Surgical vs conventional therapy for weight loss treatment of obstructive sleep apnea: a randomized controlled trial. JAMA. 2012;308(11):1142–9.PubMedCrossRef
Metadata
Title
How Physician Obesity Medicine Specialists Treated Obesity before 2012 New Drug Approvals
Authors
Stacy L. Schmidt
David Bryman
Frank L. Greenway
Ed J. Hendricks
Publication date
01-01-2015
Publisher
Springer US
Published in
Obesity Surgery / Issue 1/2015
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-014-1466-9

Other articles of this Issue 1/2015

Obesity Surgery 1/2015 Go to the issue

Brief Communication

Short- and Long-Term Hormonal and Metabolic Consequences of Reversing Gastric Bypass to Normal Anatomy in a Type 2 Diabetes Patient

Original Contributions

Very Low-Carbohydrate Ketogenic Diet Before Bariatric Surgery: Prospective Evaluation of a Sequential Diet

Original Contributions

The Efficacy of Laparoscopic Sleeve Gastrectomy in Treating Adolescent Obesity

Letter to the Editor

Laparoscopic Roux-en-Y Gastric Bypass: Creation of the Neogastric Pouch

Original Contributions

Coronary Calcium Scores 6 Years After Bariatric Surgery

Review Article

Simultaneous Sleeve Gastrectomy and Hiatus Hernia Repair: a Systematic Review